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ABSTRACT Receptor activity modifying proteins (RAMPs) are a family of single-pass transmembrane proteins that dimerize
with G-protein-coupled receptors. They may alter the ligand recognition properties of the receptors (particularly for the calcitonin
receptor-like receptor, CLR). Very little structural information is available about RAMPs. Here, an ab initio model has been
generated for the extracellular domain of RAMP1. The disulﬁde bond arrangement (Cys27-Cys82, Cys40-Cys72, and Cys57-
Cys104) was determined by site-directed mutagenesis. The secondary structure (a-helices from residues 29–51, 60–80, and
87–100) was established from a consensus of predictive routines. Using these constraints, an assemblage of 25,000 structures
was constructed and these were ranked using an all-atom statistical potential. The best 1000 conformations were energy
minimized. The lowest scoring model was reﬁned by molecular dynamics simulation. To validate our strategy, the same
methods were applied to three proteins of known structure; PDB:1HP8, PDB:1V54 chain H (residues 21–85), and PDB:1T0P.
When compared to the crystal structures, the models had root mean-square deviations of 3.8 A˚, 4.1 A˚, and 4.0 A˚, respectively.
The model of RAMP1 suggested that Phe93, Tyr100, and Phe101 form a binding interface for CLR, whereas Trp74 and Phe92 may
interact with ligands that bind to the CLR/RAMP1 heterodimer.
INTRODUCTION
G-protein-coupled receptors (GPCRs) represent one of the
largest protein families within the human genome. They have
a characteristic architecture, consisting of seven transmem-
brane (TM) helices. Ligands bind to the extracellular face of
the receptor or to a pocket formed within the TM region. In
contrast, G-proteins bind to the intracellular face of the
receptor.
Until recently, GPCRs were considered to act essentially
as monomers. However, there is now considerable evidence
that many form dimers or other oligomers (1). Most attention
has been focused on dimers between GPCRs, but other
proteins can also be involved. These include the family of
receptor activity modifying proteins (RAMPs). These were
ﬁrst identiﬁed as partners for the calcitonin receptor-like
receptor (CLR). CLR by itself is unable to bind any ligand;
however, in the presence of RAMP1 it functions as a recep-
tor for calcitonin gene-related peptide (CGRP), whereas in
the presence of RAMP2 it becomes an adrenomedullin recep-
tor. The CLR/RAMP3 complex also preferentially binds
AM, but it has a greater afﬁnity for CGRP than CLR/
RAMP2 (2). Subsequently it has been shown that RAMPs
can associate with a number of other receptors, including the
calcitonin, parathyroid hormone 1 and 2, vasoactive intes-
tinal peptide/pituitary adenylate cyclase activating polypep-
tide (VPAC1, VPAC2), glucagons, and calcium-sensing
GPCRs (3–5).
All three RAMPs are thought to be built around a common
architecture (2,6) (Fig. 1). They have a short, intracellular
C-terminus followed by a single TM region. The largest part of
the protein is the extracellular domain; ;90 amino acids for
RAMP1andRAMP3,whereas for humanRAMP2 this domain
is 13 residues longer.All RAMPs have four conserved cysteine
residues; RAMP1 and RAMP3 have an additional pair.
It seems that the N-terminus is the major determinant of
ligand binding (7,8). The structure-function relationship for
RAMP2 andRAMP3 have been investigated by use of protein
chimeras; these have identiﬁed residues 86–92 of human
RAMP2and 59–65of humanRAMP3 as key epitopes forAM
binding (9). Deletion analysis of human RAMP3 suggested
that residues 91–103 formed an important epitope for CGRP
binding (10). In human RAMP1, Trp74 is important for high-
afﬁnity binding of BIBN4096BS, a nonpeptide antagonist of
CGRP; the mutation W74K substantially reduced antagonist
afﬁnity (11). There is no structural explanation for the effect
of any of these mutants, and it is unclear whether the residues
or epitopes make direct contact with the ligands or act in-
directly to stabilize ligand binding sites. In addition, the
cysteines in the N-terminus probably form disulﬁde bonds.
Although some information has been obtained from previous
studies (12), to date, there has not been any systematic
mutagenesis study of their topology.
In this study we have produced mutant RAMP1 constructs
which incorporate all possible pairwise combinations of Cys
to Ala mutants, to determine the organization of the disulﬁde
bond network in hRAMP1. In addition, we have produced an
ab initio molecular model of RAMP1 which is entirely
consistent with the mutagenesis data presented in this study
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and also provides a mechanistic basis for mutagenesis data
previously published by other laboratories.
MATERIALS AND METHODS
Materials
Human aCGRP was from Calbiochem (Beeston, Nottingham, UK). Pep-
tides were dissolved in distilled water and stored as aliquots at 20C in
nonstick microcentrifuge tubes (Thermo Life Sciences, Basingstoke, UK).
Unless otherwise speciﬁed, chemicals were from Sigma or Fisher (Lough-
borough, UK). Cell culture reagents were from Gibco BRL (Paisley,
Renfrewshire, UK) or Sigma. [125I]-iodohistidyl8-human aCGRP (2000
Ci/mmol) was from Amersham Biosciences (Chalfont, UK).
Expression constructs and mutagenesis
HA-Human CLR (hCLR) and Myc-Human RAMP1 (hRAMP1) were
provided by Dr. S. M. Foord (GlaxoWellcome, Stevenage, UK) and sub-
cloned into the vectors pcDNA3.1() and pcDNA3.1(1) (Invitrogen, Renfrew,
UK), respectively, before mutagenesis. Mutagenesis was carried out using
the QuikChange site-directed mutagenesis kit (Stratagene, Cambridge, UK),
following the manufacturers instructions. Forward and reverse oligonucle-
otide primers were designed with single base changes to incorporate amino
acid point mutations protein and to engineer restriction sites to aid screening
of mutants in the ﬁnal constructs. The primers were synthesized by
Invitrogen.
Plasmid DNA was extracted from the cultures using a Wizard-Prep DNA
extraction kit according to the manufacturer’s instructions (Promega,
Southampton, UK). The plasmid DNA was eluted in 100 ml sterile distilled
water and stored at 20C. Sequences were conﬁrmed by sequencing
(Functional Genomics, Birmingham, UK).
Cell culture and transfection
COS-7 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
(DMEM) supplemented with 10% (v/v) fetal bovine serum and 5% (v/v)
penicillin/streptomycin in a humidiﬁed 95% air/5% CO2 atmosphere. For
transfection, the cells were plated onto 48 well plates. Cells were transfected
with 10mM polyethyleneimine (13) using 1 mg DNA per well. Character-
ization of expressed receptors was performed 48–72 h after transfection.
Assay of cAMP production
Growth medium was removed from the cells and replaced with serum-free
DMEM containing 500 mM isobutylmethylxanthine for 30 min. aCGRP in
the range 10 pM to 1 mM was added for a further 15 min. Ice-cold ethanol
(95–100% v/v) was used to extract cAMP, which was subsequently
measured by radio-receptor assay as previously described (14).
Secondary structure prediction
Secondary structure prediction of 16 diverse small helical, disulﬁde
containing peptides available from the SCOP database (15) was performed
using web-based versions of JPRED (16), GORIV (17), SAM T02 (18),
PHD (19), PROF (20), and PSIpred (21). Each method was examined for
its effectiveness at predicting the boundaries of the secondary structure
obtained from the corresponding x-ray crystal structures.
Disulﬁde bonding prediction
Disulﬁde bonding patterns for 16 diverse small helical, disulﬁde containing
peptides of known structure was performed by web-based version of
DISULFIND (22), DiANNA (23), GDAP (24), DIpro (25), and PreCys (26).
Each method was tested for its effectiveness at predicting disulﬁde bonding
patterns by comparing the predicted disulﬁde bonding pattern to the actual
disulﬁde bond arrangement in the corresponding x-ray crystal structure.
Ab initio prediction of the structure of RAMP1
An in-house script was used to generate an exhaustive conformational
sampling set of 25,000 ab initio structures for the sequences corresponding
to PDB:1HP8, PDB:1V54 chain H (residues 21–85), PDB:1T0P, and
hRAMP1, using information gained from secondary structure prediction and
disulﬁde bonding information. All structures were generated using idealized
stereochemistry for all heavy atoms (N, Ca, C, and O). Side-chain
orientations were modeled using SCWRL (27). Generated models were
initially scored using an all-atom statistical potential (scop-e4-allatoms-
x-ray-scores scoring set) as described by Samudrala and Moult (28). The en-
semble of model conformations was ﬁltered on the basis of a probability dis-
crimination function (RADPF score), such that nomore than the top 1000models
were retained for energy minimization.
Minimization was performed using a l-BFGS minimization method
which utilized the AMBER all-atom force ﬁeld (parm99) together with the
Still GB/SA solvation model, as implemented in the TINKER (29).
Minimization was performed until either convergence or a 0.1 kcal mol1
cutoff point was reached. Minimized ab initio models were subsequently
ranked according to the conformational free energy of the model. Further
reﬁnement of the model was performed using a molecular dynamics (MD)
protocol described by Fan et al. (30). Brieﬂy, simulations were performed in
explicit water using GROMACS (31) in conjunction with the GROMOS96
43a1 force ﬁeld. Simulations were preformed at constant temperature and
volume in a rectangular box. Coulomb interactions were calculated using
PME and van der Waal interactions with a dual cutoff (0.9 and 1.4 nm). High
frequency oscillations were removed by replacing hydrogens with dummy
FIGURE 1 Sequence alignments of human RAMP1,
RAMP2, and RAMP3. Signal peptide shown in italics and
underlined; domain implicated in adrenomedullin binding
shown underlined; and W, Trp74 required for high afﬁnity
BIBN4096BS binding. N, glycosylated residue. Con-
served cysteines shaded gray. Residues labeled with a
single dot are conserved in the extracellular domains of
RAMP1 and RAMP3; residues labeled with two dots are
conserved in the extracellular domains of all RAMPs.
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atoms which allowed a time step of 4 fs (32). Bonding interactions were
constrained with the LINCS algorithm, whereas water molecules were con-
strained with SETTLE. Alternate cycles of MD simulation were performed
in which the charges on the three atoms of the SPC model for water were
increased by 20% followed by a further MD cycle in which the charges on
the solvent were decreased by 20% (from the initial values). Each cycle
consisted of 5-ns duration and 10 alternate cycles were complete making
each simulation 50 ns in total. Initial ab initio model building and MD
reﬁnement was performed on Pentium IV workstations operating Linux.
Data analysis
Curve ﬁtting was done with PRISM Graphpad 4 (Graphpad Software Inc.,
San Diego, CA). For cAMP studies, the data from each concentration-
response curve were ﬁtted to a sigmoidal concentration-response curve and
normalized to obtain the maximum response (Emax) and logEC50 (pEC50)
(Table 1). pEC50 and Emax values were compared by paired Student’s t-test
or by repeated measures one-way ANOVA followed by Tukey’s test. Com-
parisons were only made between wild-type (WT) and mutant data from
concomitantly transfected cells. A control WT experiment was included in
every experiment (Table 1).
RESULTS
Computational disulﬁde bond prediction
To assess the effectiveness of disulﬁde bonding pattern
prediction methods we submitted 16 sequences from the
SCOP database (p8-MTCP1, frizzled cysteine-rich domain,
anaphylotoxins, cytochrome c oxidase subunit-h categories)
to web-based disulﬁde bonding prediction servers. For our
system (small mainly helical peptides which contain disul-
ﬁde bonds) the web-based neural net server DISULFIND
(http://disulﬁnd.dsi.uniﬁ.it/) generated predicted disulﬁde
bonding patterns which were consistent with experimental
data. All cloned RAMPs were submitted to DISULFIND and
the results compared. With the exception of a RAMP
precursor from the genus Tetrodon, the predicted disulﬁde
bonding pattern was 1–5, 2–4, and 3–6 (Fig. 2).
Secondary structure prediction
Sequences from disulﬁde containing small a-helical proteins
(as deﬁned above) were used to score the effectiveness of
web-based secondary structure prediction methods. Of the
methods selected, the SAM T02 and JPRED servers gave
secondary structure predictions that were consistent with the
experimentally derived structures as deﬁned above. The
sequences for all cloned RAMPs were submitted to JPRED
and SAMT02 servers and the consensus prediction suggested
that the extracellular portion of RAMPs was composed of
three a-helical domains (helix 1, residues 29–51; helix 2,
residues 60–80, and helix 3, residues 87–100 for hRAMP1,
Fig. 2). A signal peptide was also identiﬁed at the proximal
portion of the N-terminus (residues 1–16 hRAMP1). Fur-
thermore, TMHMM (33) also predicted that the transmem-
brane domain of hRAMP1 comprised residues 118–139.
Probing the disulﬁde bonding pattern of RAMP1
using site-directed mutagenesis
To investigate the roles of the conserved Cys residues, each
was initially substituted with Ala creating the hRAMP1
TABLE 1 Disulﬁde mutants of hRAMP1
hRAMP1 mutants construct WT pEC50 pEC50 Emax
C27A 9.16 6 0.14 (3) 9.46 6 0.32 (3) 100 6 3.00 (3)
C40A 9.02 6 0.24 (3) 8.37 6 0.12* (3) 84 6 7.00 (3)
C57A 9.23 6 0.28 (3) 7.99 6 0.89*** (3) 65 6 9.00 (3)
C72A 9.37 6 0.19 (3) 8.55 6 0.39* (3) 84 6 8.00 (3)
C82A 9.24 6 0.10 (3) 9.39 6 0.21 (3) 92 6 7.00 (3)
C104A 9.22 6 0.4 (3) 8.01 6 0.27*** (3) 70 6 6.00 (3)
C27A–C40A 9.18 6 0.29 (3) .6.00 (3) ND
C27A–C57A 9.51 6 0.17 (3) .6.00 (3) ND
C27A–C72A 9.11 6 0.65 (3) .6.00 (3) ND
C27A–C82A 9.43 6 0.42 (3) 9.27 6 0.33 (3) 95 6 5.00 (3)
C27A–C104A 9.29 6 0.27 (3) .6.00 (3) ND
C40A–C57A 9.65 6 0.11 (3) .6.00 (3) ND
C40A–C72A 9.34 6 0.85 (3) 8.83 6 0.25* (3) 87 6 6.00 (3)
C40A–C82A 9.27 6 0.52 (3) .6.00 (3) ND
C40A–C104A 9.23 6 0.34 (3) .6.00 (3) ND
C57A–C72A 9.10 6 0.22 (3) .6.00 (3) ND
C57A–C82A 9.53 6 0.11 (3) .6.00 (3) ND
C57A–C104A 9.12 6 0.58 (3) 8.10 6 0.15** (3) 76 6 5.00 (3)
C72A–C82A 9.11 6 0.13 (3) .6.00 (3) ND
C72A–C104A 9.75 6 0.17 (3) .6.00 (3) ND
C82A–C104A 9.19 6 0.27 (3) .6.00 (3) ND
Values are mean 6 SE; number of determinations is shown in parentheses. Signiﬁcantly different from WT at P , 0.05 (*) or P , 0.001(***), as assessed
by one-way ANOVA with repeated measures followed by Tukey’s test. Emax is the maximum response expressed as a percentage of the response to the WT.
ND, not determined. Comparisons were only made between WT and mutant data from concomitantly transfected cells. A control WT experiment was
included in every experiment.
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mutations C27A, C40A, C57A, C72A, C82A, and C104A.
These were subsequently expressed in COS-7 cells, which
had no endogenously expressed RAMP1 and their pharma-
cological characteristics assessed (Table 1 and Fig. 3). The
single Ala substitutions to Cys27 and Cys82 were well-
tolerated and resulted in WT-like pEC50 values. However,
the substitutions to Cys40, Cys57, Cys72, and Cys104 resulted
in a signiﬁcantly reduced pEC50 value compared to WT
(Table 1). Visual inspection of these data revealed three
different patterns of signaling which could be classiﬁed as i),
WT-like; ii), intermediate decrease in potency; and iii), large
decrease in potency. This is entirely consistent with a
disulﬁde bonding pattern of 1–5, 2–4, and 3–6 (Fig. 3) which
was the computational disulﬁde bonding prediction. This
disulﬁde bond arrangement was further tested by the
generation of three double Cys substitutions (C27A/C82A,
C40A/C72A, and C57A/C104A). Interestingly, the pEC50
for the double mutations was reduced only by the same
extent as observed for the corresponding single mutations
(Table 1). To ensure that the absence of an increased effect
for the double mutations compared to the individual Cys
substitutions was not a system artifact, 12 further double
Cys mutations were generated (Table 1). These double Cys
mutants sampled all remaining possible disulﬁde bond
pairings. However, these mutant constructs were unable to
generate an agonist-induced intracellular response (Table 1).
Overall, these data provide evidence that the disulﬁde
bonding pattern in hRAMP1 is 1–5, 2–4, and 3–6.
Model building
Information gained from the secondary structure predictions
and the mutagenic data was used as restraints for the ab initio
modeling of hRAMP1. Several attempts to use existing ab
initio modeling methods to generate hRAMP1 structure were
unsuccessful and unable to generate structures which were
consistent with the disulﬁde bonding pattern indicated by our
mutagenesis studies. Furthermore, no suitable templates
were found using web-based searches such as 3DJURY (34)
for construction of homology models. We have therefore
FIGURE 2 Primary sequence of extracellular res-
idues (26–109) of hRAMP1. Shown on the diagram
are the consensus a-helical regions (dotted) as pre-
dicted by JPED and SAMT02 servers and the ﬁnal
positions of the helices (solid) after MD reﬁnement.
Also shown on the diagram is the disulphide pattern
Cys27(1)-Cys82(5), Cys40(2)-Cys72(4) and Cys57(3)-
Cys104(6) as suggested by in silico prediction and
conﬁrmed by mutagenesis.
FIGURE 3 CGRP-stimulated cAMP production in mu-
tated RAMPs. Cos 7 cells were transfected with CL/WT
hRAMP1 or CL/mutant hRAMP1 and assayed for CGRP-
stimulated cAMP production. (n) WT type receptors.
Mutant receptors are as indicated. Data are representative
of three similar experiments. Points are the mean 6 SE of
triplicate determinations.
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developed an ab initio modeling protocol which was able to
include information such as disulﬁde bonding information
and secondary structure to generate an initial ensemble of
structures which were scored using a two-tier approach. The
lowest energy structure was then further reﬁned using MD.
To assess the effectiveness of an ab initio modeling
method, it must be shown to be able to predict the con-
formation of proteins whose structure has been solved at
high resolution. Three helical disulﬁde containing peptides
(PDB:1HP8, PDB:1V54, and PDB:1T0P) from the SCOP
database (http://scop.mrc-lmb.cam.ac.uk/scop/) were ran-
domly picked to test the method. Some 25,000 initial decoy
structures were generated using information gained from
secondary structure prediction and disulﬁde bonding pat-
terns. Importantly, no information was used from the x-ray
crystal structures. These were scored using the RAPDF
potential function (28). The top 1000 lowest energy confor-
mations were retained and energy minimized using the
AMBER99 force ﬁeld as implemented in TINKER (29).
Visual inspection of the resulting structures revealed that the
best 20 lowest energy structures converged onto a single
conformation for the modeled structures for PDB:1HP8,
PDB:1V54, and PDB:1T0P. These intermediate ab initio
structures were compared to the corresponding x-ray crystal
coordinates and revealed that the Ca root mean-squared
deviation (RMSD) was 5.28 A˚, 4.8 A˚, and 5.4 A˚ for
PDB:1HP8, PDB:1V54 chain H (residues 21–85), and
PDB:1T0P, respectively. This demonstrated that the use of
the AMBER/GBSA energy function resulted in the selection
of an ab initio model with a fold that was close to the native
structure. Further reﬁnement of these intermediate structures
was achieved through the use of 50 ns MD simulations
which generated an improved structure that exhibited a Ca
RMSD of 3.8 A˚, 4.1 A˚, and 4.0 A˚ when compared to the
x-ray crystal structures PDB:1HP8, PDB:1V54 chain H
(residues 21–85), and PDB:1T0P, respectively (Fig. 4).
The validated ab initio approach was then used to generate
a structural model for hRAMP1. Initial model building
utilized information gained from secondary structure pre-
dictions and the experimentally conﬁrmed disulﬁde bonding
pattern. In addition, a further set of decoy structures were
generated which utilized the secondary structure prediction
information but only used the disulﬁde pattern of 2–4 and
3–6 as restraints. This step was performed as the mutations
C27A and C82A did not perturb intracellular signaling. For
both sets of conditions 25,000 decoys were generated and the
results compared; both generated similar sets of low energy
structures. The best of these were then reﬁned further using
the same MD protocol as applied to the ab initio models of
the three control peptides of known structure cited above. In
the resulting structure (Fig. 5), the three a-helices were
retained which conﬁrmed the initial secondary structure
prediction, however the start and end points of the a-helices
as well as their positioning with respect to one another, were
different from the initial conformation. Interestingly, the
structures from the two sets of initial disulﬁde bonding
conditions converged to a single structure.
DISCUSSION
In this study, we present a structure for hRAMP1 obtained by
molecular modeling which is supported by pharmacological
characterization of mutant hRAMP1 constructs. Further-
more, the approaches presented in this study are likely to have
widespread utility for studying cysteine-containing peptides
in general.
A key step in determining the structure of any cysteine-
containing protein is to establish the disulﬁde bonding
FIGURE 4 Comparison of the reﬁned ab initio models (left) and the
corresponding x-ray crystal structure (right) for PDB:1HP8, PDB:1V54
and PDB:1T0P after 50ns of MD simulation. The structures were compared
and revealed a Ca RMSD of 3.8 A˚, 4.1 A˚, and 4.0 A˚ for the PDB:1HP8,
PDB:1V54, and PDB:1T0P x-ray crystal structures, respectively.
FIGURE 5 Ab initio model of hRAMP1. Panels A and B show the
architecture of hRAMP1 with three helices and interconnecting loops. (A)
Previous studies have highlighted Phe93 and Tyr100 as being important in
cell surface expression. The ab initio model of hRAMP1 reveals that these
residues are located in a cleft between helix1 and helix3. (B) Location of
Phe92, which has been shown to affect ligand binding, but has little effect on
cell surface expression. Also shown in B is the location of Trp74, a residue
that has been implicated in the high afﬁnity binding of the non-peptide
antagonist BIBN4096BS.
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pattern and any molecular model of such proteins has to be
consistent with this information. Although the effect of
mutating individual cysteines in RAMP1 has been reported
(12), the disulﬁde bonding pattern was unknown before this
study. To establish the disulﬁde bonding pattern of RAMP1,
it was necessary to undertake systematic Cys substitution, to
produce a series of pairwise double Cys mutants. The func-
tional ramiﬁcations of these Cys-substituted mutants were
then examined for lack of additivity. Lack of an additive
effect in double mutants is strong evidence that the two Cys
residues contribute to the same bond (35). In this study, our
results unambiguously demonstrate that the disulﬁde bond
pattern is 1–5, 2–4, 3–6, which is consistent with a recent
abstract using mass spectrometry based analysis (36).
Furthermore, it is commonly believed that RAMPs are built
from a common architecture (6), therefore this disulﬁde bond-
ing pattern is likely to be found in the other members of the
RAMP family.
This information allowed us to evaluate the various
modeling routines that are available to predict disulﬁde
bonding patterns. We used a dataset of disulﬁde-containing
small a-helical proteins of known structure and based on
this, selected the neural net-based package, DISULFIND.
Not only did this successfully predict the disulﬁde bond
arrangement that was observed experimentally, it also
predicted the same pattern for other known RAMP se-
quences, with the exception of a RAMP precursor from the
genus Tetrodon. We then extended this approach to select
the best secondary structure prediction method. We used a
consensus of two methods and again these also predicted that
all members of the RAMP family share the same structure;
an N-terminus composed of three helices and a single
transmembrane helix. The model itself was built using
idealized a-helices and systematically sampled the confor-
mational space to identify a low energy bundle. Interestingly,
even though a ‘‘brute force’’ approach was used to generate
the initial structures (for models of both the x-ray crystal
structure set and the model of hRAMP1) the two-tiered
approach of using the RAPDF score and the AMBER/GBSA
force ﬁeld resulted in structures which were close to the
native conformation. In addition, the convergence of the
lowest energy structure onto one conformation suggests that
the conformational space was adequately sampled by the
initial packing search. These structures were reﬁned using an
MD protocol described by Fan and Mark (30). In all cases,
marked improvement from the initial conformations were
observed in the Ca RMSD for the ab initio structures of
PDB:1HP8, PDB:1V54, and PDB:1T0P. This suggested that
this method was also applicable for the reﬁnement of the
hRAMP1 structure, which used the same initial packing
protocol. The MD reﬁned structure of hRAMP1 exhibited
three a-helices which is consistent with the secondary
structure predictions. Furthermore, Fan and Mark (30) also
demonstrated that wrongly assigned secondary structure was
not stable in their protocols and despite some unraveling of
the extreme ends of the hRAMP1 helices, the secondary
structure was stable for the 50 ns time lengths of the
simulations. In addition to using the disulﬁde constraints of
1–5, 2–4, and 3–6 we also employed the disulﬁde bonding
pattern of 2–4 and 3–6 in ab initio model building. This
revealed that the loss of the 1–5 disulﬁde restraint had little
effect on the conformation of the lowest energy structure and
that the loss of the disulﬁde bond between Cys27 and Cys82
has little effect on the ab initio folding landscape of
hRAMP1. Furthermore, reﬁnement for both sets of disulﬁde
bond arrangements for hRAMP1 modeling (disulﬁde bonds
between Cys 1–5, 2–4, 3–6 versus disulﬁde bonds between
Cys 2–4 and 3–6) converged onto a single conformation.
This reveals that a disulﬁde bond between Cys1–5 does not
greatly affect the tertiary fold of the RAMP1 protein and
thereby provides the molecular basis underlying the wild-
type characteristics of the C27A, C82A, and C27A/C82A
mutant RAMP1 constructs.
It is possible to use the model of RAMP1 to examine
previous mutagenesis studies reported by others. The most
detailed work on structure-function relationships for RAMP1
was carried out by Kuwasako and colleagues (10), who
identiﬁed residues 91–103 as particularly important. This essen-
tially corresponds to helix 3 in our model structure (Fig. 5).
Mutations of Phe93, Tyr100, and Phe101 to Ala signiﬁcantly
reduced cell-surface expression of RAMP1; by contrast
L94A increased surface expression, most likely due to relief
of steric hindrance. The mutants F92A and H97A showed
reasonable expression but reduced CGRP binding. Mutation
of the other residues in this segment to Ala (Arg91, Val96,
Arg99, Arg102, and Ser103) was without effect on binding or
expression. Using our model of RAMP1 to interpret the
effect of these point mutations revealed that almost all of the
residues that alter expression, or CGRP binding, face into
the groove between the three helices. Consequently, it is
possible that these residues may contribute to the packing of
the helices of RAMP1 and thus its stability. However,
RAMP1 requires heterodimerization with CLR for cell
surface expression (37). Thus it is possible that these
residues are required for a binding site between the RAMP
and CLR. It has been suggested that the increase in surface
expression seen with L94A is due to relief of steric hindrance
between the Leu side chain and CLR. In our model, Leu94
could interact with a portion of CLR that packed into the
interhelical groove. F92A, however (reduced binding of
CGRP but WT-like cell-surface expression of RAMP1) is
faced away from the groove and could conceivably interact
directly with CGRP. It should be noted that in the study by
Kuwasako and colleagues (10), CGRP binding was only
assessed at a single concentration of radioligand, used well
below its Kd; thus the small (twofold) reduction in binding
seen with F92A (and H97A) could have been due to an
altered Kd. In a separate study, Trp
74 was identiﬁed as a key
residue for the binding of the nonpeptide antagonist
BIBN4096BS (11). Although Trp74 is located on helix 2, it
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nevertheless faces in the same direction as Phe92, consistent
with a role for these residues in ligand binding (38).
Although RAMP1 is not glycosylated, RAMP3 has four
potential glycosylation sites (Fig. 1). Given that the model-
ing indicates that the two proteins should have essentially
similar structures, it is not unreasonable to predict that the
equivalent positions to the RAMP3 glycosylation sites
(Gln28, Asp58, Asp71, and Ser103 of RAMP1) should also be
sterically suitable for glycosylation in RAMP1. Indeed,
mutating the latter three residues to asparagines produces
glycosylation-competent forms of RAMP1 (39). In the
model, all of the residues are in sterically unconstrained
positions that could readily accommodate carbohydrate
chains. The location of Asp71 with respect to the critical
Trp74 is interesting; the side chain of Trp74 is predicted to
project below that of Asp71 so that it is closer to the plasma
membrane. Furthermore it points away from Asp71 by an
angle of;90. Thus, Trp74 could interact either directly with
BIBN4096BS or with another part of CLR without any
interference from carbohydrate.
In conclusion we have generated an ab initio model of
hRAMP1 which is consistent with mutagenic data presented
above and also provides a rational mechanistic explanation
of data published by others. This is the ﬁrst investigation into
a plausible model of hRAMP1 and the data obtained may
be applicable to other members of the RAMP family.
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